Respiratory syncytial virus (RSV) remains a significant yet frequently overlooked threat to the elderly population. Recent research highlights that the RSV infection burden in long-term care facilities (LTCFs) is much higher than previously estimated. While many clinicians associate RSV primarily with pediatric patients, older adults residing in institutional settings face a substantial risk of severe outcomes. Because these infections often present with atypical symptoms or remain entirely asymptomatic, traditional diagnostic methods frequently fail to capture the true scale of the problem.

Analyzing the RSV Infection Burden in Institutional Settings

A comprehensive study conducted in Sweden between 2021 and 2024 utilized serological monitoring to track respiratory viruses among 1,622 LTCF residents. The researchers analyzed capillary blood samples to identify antigen-specific antibody responses. Consequently, they discovered that the RSV infection burden peaked during specific seasonal windows, notably in the spring of 2022 and the winter of 2022-2023. Interestingly, the data showed that RSV-related antibody responses were more prevalent than those for influenza A or influenza B during these periods.

Furthermore, the study demonstrated that a high proportion of residents experienced significant rises in RSV-specific IgG and IgM levels. This finding suggests frequent exposure and reinfection within these facilities. However, many of these cases did not trigger standard clinical alerts. This discrepancy occurs because elderly patients often do not exhibit the classic febrile or respiratory signs seen in younger cohorts. Therefore, relying solely on symptom-based testing significantly underestimates the actual viral circulation in care homes.

Clinical Implications for Geriatric Care

In India, where the geriatric population is expanding rapidly, these findings carry immense clinical weight. Most respiratory surveillance in India focuses on SARS-CoV-2 and Influenza, yet RSV may be contributing silently to morbidity in nursing homes and palliative care centers. Additionally, the introduction of RSV vaccines makes it crucial for healthcare providers to identify at-risk populations accurately. By understanding that the RSV infection burden is substantial, physicians can better advocate for preventive measures and improved diagnostic protocols.

Moreover, the study highlighted that comorbidities did not necessarily predict the likelihood of infection, though they certainly influence the severity of the outcome. In contrast to younger adults, the elderly maintain a baseline of inflammation that can mask acute viral responses. Consequently, clinicians must maintain a high index of suspicion for RSV during peak seasons, even when patients present with vague symptoms like lethargy or confusion rather than a cough.

Frequently Asked Questions

Why is RSV often underdiagnosed in older adults?

RSV often presents atypically in seniors, lacking the clear respiratory distress seen in children. Many elderly patients exhibit non-specific symptoms such as fatigue or decreased appetite, leading clinicians to overlook viral causes.

How does the RSV infection burden compare to influenza?

Serological evidence suggests that in institutional settings, the RSV infection burden can actually exceed that of seasonal influenza. This highlights the need for broader multiplex testing beyond just flu and COVID-19.

What are the benefits of identifying RSV in care facilities?

Accurate identification allows for better infection control measures and the targeted use of upcoming vaccines. It also prevents the unnecessary use of antibiotics by confirming a viral etiology for respiratory decline.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Moar P et al. Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities. BMC Med. 2026 Feb 24. doi: 10.1186/s12916-026-04700-7. PMID: 41731510.

Taylor & Francis. Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia. 2025.

CDC. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2023.